These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9634293)

  • 1. Can HSV latency be conquered by current antiviral therapies?
    Simmons A; Field HJ
    Sex Transm Infect; 1998 Feb; 74(1):1-2. PubMed ID: 9634293
    [No Abstract]   [Full Text] [Related]  

  • 2. Herpes simplex virus latency and nucleoside analogues.
    Efstathiou S; Field HJ; Griffiths PD; Kern ER; Sacks SL; Sawtell NM; Stanberry LR
    Antiviral Res; 1999 Apr; 41(3):85-100. PubMed ID: 10320042
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic implications of new insights into the critical role of VP16 in initiating the earliest stages of HSV reactivation from latency.
    Thompson RL; Sawtell NM
    Future Med Chem; 2010 Jul; 2(7):1099-105. PubMed ID: 21426158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early therapy with valaciclovir or famciclovir reduces but does not abrogate herpes simplex virus neuronal latency.
    Field HJ; Thackray AM
    Nucleosides Nucleotides Nucleic Acids; 2000; 19(1-2):461-70. PubMed ID: 10772727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of HSV cell-to-cell spread by lactoferrin and lactoferricin.
    Jenssen H; Sandvik K; Andersen JH; Hancock RE; Gutteberg TJ
    Antiviral Res; 2008 Sep; 79(3):192-8. PubMed ID: 18456345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral activity of Australian tea tree oil and eucalyptus oil against herpes simplex virus in cell culture.
    Schnitzler P; Schön K; Reichling J
    Pharmazie; 2001 Apr; 56(4):343-7. PubMed ID: 11338678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HSV shedding.
    Sacks SL; Griffiths PD; Corey L; Cohen C; Cunningham A; Dusheiko GM; Self S; Spruance S; Stanberry LR; Wald A; Whitley RJ
    Antiviral Res; 2004 Aug; 63 Suppl 1():S19-26. PubMed ID: 15450382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients.
    Levin MJ; Bacon TH; Leary JJ
    Clin Infect Dis; 2004 Nov; 39 Suppl 5():S248-57. PubMed ID: 15494896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of HSV-1 infection with immunoglobulin or acyclovir: comparison of their effects on viral spread, latency, and reactivation.
    LeBlanc RA; Pesnicak L; Godleski M; Straus SE
    Virology; 1999 Sep; 262(1):230-6. PubMed ID: 10489356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective, case-control study of acyclovir resistance in herpes simplex virus.
    Malvy D; Treilhaud M; Bouée S; Crochard A; Vallée D; El Hasnaoui A; Aymard M;
    Clin Infect Dis; 2005 Aug; 41(3):320-6. PubMed ID: 16007528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cutaneous and mucosal herpes. Epidemiology, physiopathology, diagnosis, prognosis, treatment].
    Laurent R; Drobacheff C
    Rev Prat; 2000 May; 50(10):1127-34. PubMed ID: 10905100
    [No Abstract]   [Full Text] [Related]  

  • 12. New anti-HSV therapeutics target the helicase-primase complex.
    Crumpacker CS; Schaffer PA
    Nat Med; 2002 Apr; 8(4):327-8. PubMed ID: 11927930
    [No Abstract]   [Full Text] [Related]  

  • 13. Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo.
    Sawtell NM; Thompson RL; Stanberry LR; Bernstein DI
    J Infect Dis; 2001 Oct; 184(8):964-71. PubMed ID: 11574910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-viral activity of the extracts of a Kenyan medicinal plant Carissa edulis against herpes simplex virus.
    Tolo FM; Rukunga GM; Muli FW; Njagi EN; Njue W; Kumon K; Mungai GM; Muthaura CN; Muli JM; Keter LK; Oishi E; Kofi-Tsekpo MW
    J Ethnopharmacol; 2006 Mar; 104(1-2):92-9. PubMed ID: 16198524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amphipathic DNA polymers are candidate vaginal microbicides and block herpes simplex virus binding, entry and viral gene expression.
    Guzman EM; Cheshenko N; Shende V; Keller MJ; Goyette N; Juteau JM; Boivin G; Vaillant A; Herold BC
    Antivir Ther; 2007; 12(8):1147-56. PubMed ID: 18240855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro antiviral activity of distamycin A against clinical isolates of herpes simplex virus 1 and 2 from transplanted patients.
    Matteoli B; Bernardini S; Iuliano R; Parenti S; Freer G; Broccolo F; Baggiani A; Subissi A; Arcamone F; Ceccherini-Nelli L
    Intervirology; 2008; 51(3):166-72. PubMed ID: 18663321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intradermal doxorubicin reduces ganglionic reactivation of latent herpes simplex virus in mice after pretreatment with hypertonic saline.
    Sekizawa T; Openshaw H; Itoyama Y
    J Med Virol; 2003 Jun; 70(2):263-6. PubMed ID: 12696114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are we too cavalier about antiviral prophylaxis?
    Onwudiwe OC; Marmur ES; Cohen JL
    J Drugs Dermatol; 2013 Feb; 12(2):199-205. PubMed ID: 23377394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Echinacea purpurea polysaccharide reduces the latency rate in herpes simplex virus type-1 infections.
    Ghaemi A; Soleimanjahi H; Gill P; Arefian E; Soudi S; Hassan Z
    Intervirology; 2009; 52(1):29-34. PubMed ID: 19372701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical utility of susceptibility testing of herpes simplex virus to acyclovir].
    Otegui M; Rabella N; Labeaga R; Herrero M; Margall N; Muñoz JM; Prats G
    Rev Esp Quimioter; 2001 Dec; 14(4):351-7. PubMed ID: 11856981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.